Welcome to our dedicated page for Hydreight Tech news (Ticker: HYDTF), a resource for investors and traders seeking the latest updates and insights on Hydreight Tech stock.
Hydreight Technologies Inc. reports on a U.S.-focused digital health infrastructure business that combines telehealth, pharmacy fulfillment, clinical coverage and on-demand healthcare services. Company news commonly covers financial results, platform operating leverage, product-order activity, partner onboarding and expansion of the VSDHOne direct-to-consumer platform.
Recurring developments also include new healthcare service categories, such as at-home STI pre-screening, updates on platform licenses and modular workflow capabilities, revenue guidance, profitability commentary and capital actions such as normal course issuer bid activity.
Hydreight Technologies (OTCQB: HYDTF) has appointed Dr. Jeremy Roebuck as a director of the company, effective May 5, 2025. Dr. Roebuck, who has served on Hydreight's Board of Advisors since December 12, 2022, fills the vacancy created by the resignation of Alexandros Tzilios. Hydreight is a North American integrated mobile clinical network of nurses, doctors, and pharmacy distribution.
Dr. Roebuck expressed enthusiasm about joining the board at a crucial growth phase, highlighting the company's focus on delivering healthcare through a compliant, tech-enabled platform. He aims to contribute to scaling the platform and expanding Hydreight's presence across North America.
Hydreight Technologies reported strong financial results for Q4 and full-year 2024, marking significant growth milestones. The company achieved record revenue of $22.32 million in topline revenue (up 31% from 2023) and $16.04 million in GAAP revenue (up 39% from 2023).
Key achievements include reaching positive Adjusted EBITDA of $490K compared to -$1.38M in 2023, and positive cash flow from operations. The company's success was recognized through rankings on Deloitte's Technology Fast 50™ (#9 in Canada) and Fast 500™ (#56 in North America).
The mobile healthcare platform, operating across all 50 U.S. states, secured $5.4M in financing and expanded its services through VSDHOne platform. With a network of 3,000+ nurses and 200+ physicians serving 700+ cities, Hydreight's 2025 strategy focuses on scaling franchise partnerships, improving pharmacy margins, and launching new wellness categories.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) announced its upcoming presentation at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025. CEO Shane Madden will present at 12:30 PM PST and host a Q&A session.
The company is building one of the largest mobile clinical networks in the US, offering services like weight loss treatments, hormone therapy, IV wellness, and at-home testing. Recent achievements include:
- Launch of Liraglutide and sublingual semaglutide on VSDHOne platform
- US partnership with 'Dr. Frank's Method' GLP-1 weight-loss brand serving 70,000+ clients
- Launch of $10M health accelerator fund for emerging healthcare brands
- Ranked #13 on Financial Times' Americas' Fastest Growing Companies 2025
- #56 on Deloitte's Technology Fast 500™
- Top 50 on TSX Venture 50
Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Liraglutide, enhancing its GLP-1 weight management portfolio. The company's comprehensive GLP-1 offerings now include Semaglutide (weekly injectable), Tirzepatide (dual-action, weekly injectable), Liraglutide (daily injectable), and Sublingual & Buccal GLP-1s (needle-free administration).
The addition of Liraglutide introduces a stable, patent-free option amid increasing GLP-1 medication demand. The VSDHOne platform facilitates telehealth consultation, prescription, and nationwide delivery across 50 US states. With over 400 licenses sold across the U.S., Hydreight's platform supports multiple delivery methods including injectables, sublingual, and buccal options.
Notable achievements include ranking 56th on the 2024 Deloitte Technology Fast 500™, recognition as a Top 50 TSX Venture Exchange Company, and ranking 13th among Americas' Fastest Growing Companies by Financial Times in 2025.
Hydreight Technologies (HYDTF) has announced a strategic partnership with renowned endocrinologist Dr. Franklin Joseph to launch his successful weight-loss brand, 'Dr. Frank's Method,' in the United States through their VSDHOne telehealth platform.
The partnership combines Dr. Frank's GLP-1 weight-loss methodology, which has served over 500,000 global patients, with Hydreight's nationwide telehealth infrastructure. The program includes access to branded GLP-1 medications, specialist weight-loss nurses, and personalized lifestyle support.
Key partnership terms include:
- 50/50 profit-sharing structure
- Waived platform fees from Hydreight
- Committed monthly U.S. marketing spend from Dr. Frank
This collaboration targets the expanding U.S. weight-loss market, where over 42.4% of adults have obesity. The global weight-loss market is projected to exceed $400 billion by 2030, with GLP-1 prescriptions showing a 400% increase and spending rising by 500%.
Hydreight Technologies (OTCQB: HYDTF) has been named to the Financial Times list of The Americas' Fastest Growing Companies 2025, validating its remarkable growth trajectory in the digital health platform sector. The company has achieved a stunning 2,400% revenue growth from $400K to nearly $24M in just five years, while maintaining positive Adjusted EBITDA.
Ranked 56th on Deloitte's Technology Fast 500™ and 9th in Canada, Hydreight met strict criteria including: minimum revenue of $100,000 in 2020 and $1.5M in 2023, independent company status, and primarily organic growth. The company is expanding into high-growth sectors including:
- GLP-1 weight-loss medications
- Anti-aging therapies
- IV wellness
- At-home testing
- Chronic care management
The company plans to launch new offerings, scale M&A, and expand its national footprint in 2025, positioning itself as a leader in direct-to-consumer telehealth services across the U.S.
Hydreight Technologies (OTCQB: HYDTF) has expanded its VSDHOne telehealth platform by introducing new oral weight loss therapies across three delivery formats: sublingual, capsule, and tablet. The company, which operates a mobile clinical network across all 50 U.S. states, now offers multiple weight loss treatments including Semaglutide Sublingual, Sermorelin Sublingual, Advanced Weight Management Support Capsule, Metformin HCl ER Tablets, and Phentermine HCl Tablets.
With a network of over 3,000 licensed nurses and 100+ doctors, Hydreight aims to capitalize on the global weight loss market, projected to exceed $400 billion by 2030. The company has engaged GRA Enterprises for a three-month term to provide marketing and awareness services for US$30,000.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) has been named to the 2025 TSX Venture 50™ list, recognizing top-performing companies from over 1,600 TSXV issuers based on market capitalization growth, share price appreciation, and trading volume. The mobile clinical network and medical platform also achieved significant recognition in 2024, ranking 9th in Canada and 56th in North America on Deloitte's Technology Fast 500 list.
The company's VSDHOne telemedicine and e-commerce platform is now fully operational across all 50 U.S. states. CEO Shane Madden highlighted their commitment to innovation in mobile healthcare and telemedicine, focusing on enabling licensed healthcare professionals to deliver care at home, in clinics, and through direct-to-consumer models.
Looking ahead to 2025, Hydreight plans to focus on scaling VSDHOne and the Accelerator Program, optimizing product offerings for higher margins, and exploring 503A and 503B licensing opportunities for vertical integration.
Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Nicotinamide Adenine Dinucleotide (NAD+) therapy in three new delivery formats: patch, injection, and nasal spray. This expansion targets the growing anti-aging market, valued at $73 billion in 2024 and projected to reach $140.94 billion by 2034.
The company now offers NAD+ through three delivery methods: intramuscular/subcutaneous injection for rapid absorption, daily intranasal spray for convenience, and IonToPatch featuring 4-hour wear time and 80 mA/min delivery with 1mL fill volume. NAD+ therapy aims to provide benefits including improved cognitive function, enhanced energy levels, weight management support, and potential neuroprotective effects.
This development strengthens Hydreight's position in providing accessible wellness solutions through its nationwide telehealth network across 50 U.S. states.